Powles T, Park SH, Caserta C et al (2023) Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 Trial after ≥2 years of follow-Up. J Clin Oncol 41:3486–3492. https://doi.org/10.1200/JCO.22.01792

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Eng J Med 384:1125–1135. https://doi.org/10.1056/NEJMoa2035807

Article  CAS  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

Article  CAS  PubMed  Google Scholar 

Ok CY, Hasserjian RP, Fox PS et al (2014) Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 28:185–189. https://doi.org/10.1038/leu.2013.191

Article  CAS  PubMed  Google Scholar 

Zahr AA, Kavi AM, Mukherjee S, Zeidan AM (2017) Therapy-related myelodysplastic syndromes, or are they? Blood Rev 31:119–128. https://doi.org/10.1016/j.blre.2016.11.002

Article  PubMed  Google Scholar 

McNerney ME, Godley LA, Le Beau MM (2017) Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Rev Cancer 17:513–527. https://doi.org/10.1038/nrc.2017.60

Article  CAS  Google Scholar 

Kuendgen A, Nomdedeu M, Tuechler H et al (2021) Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS. Leukemia 35:835–849. https://doi.org/10.1038/s41375-020-0917-7

Article  CAS  PubMed  Google Scholar 

Haferlach T, Nagata Y, Grossmann V et al (2013) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241–247. https://doi.org/10.1038/leu.2013.336

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fianchi L, Pagano L, Piciocchi A et al (2015) Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian Network on secondary leukemias. Am J Hematol 90:E80–E85. https://doi.org/10.1002/ajh.23966

Article  CAS  PubMed  Google Scholar 

Berggren DM, Garelius H, Hjelm PW et al (2023) Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective. Leukemia 37:1103–1112. https://doi.org/10.1038/s41375-023-01864-6

Article  CAS  Google Scholar 

Theodore C, Bayle C, Bernheim A, Wibault P (2002) Secondary leukaemia after treating advanced bladder cancer with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and radiotherapy”. BJU Int 90:470–471. https://doi.org/10.1046/j.1464-410X.2002.02866.x

Article  CAS  PubMed  Google Scholar 

Yanagida K, Kawai T, Seito T, Matsumoto K, Kaneko T, Nakagawa T (2024) Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma. IJU Case Rep 7:316–319. https://doi.org/10.1002/iju5.12734

Article  PubMed  PubMed Central  Google Scholar 

Travis LB, Holowaty EJ, Bergfeldt K et al (1999) Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340:351–357. https://doi.org/10.1056/NEJM199902043400504

Article  CAS  PubMed  Google Scholar 

Michot JM, Lazarovici J, Tieu A et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72–90. https://doi.org/10.1016/j.ejca.2019.07.014

Article  CAS  PubMed  Google Scholar 

Miyake M, Shimizu T, Oda Y et al (2023) Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study. Jpn J Clin Oncol 53:253–262. https://doi.org/10.1093/jjco/hyac186

Article  PubMed  Google Scholar 

Barthelemy P, Loriot Y, Thibault C et al (2024) Updated results from AVENANCE: real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment. J Clin Oncol 42:561–561. https://doi.org/10.1200/JCO.2024.42.4_suppl.561

Article  Google Scholar 

Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C (2017) Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 28:2670–2679. https://doi.org/10.1093/annonc/mdx360

Article  CAS  PubMed  PubMed Central  Google Scholar